Bioavailability Clinical Development Research 
Pharmaceutical Technology
MAY 31, 2023
It is expected to accelerate the development of CFT8919 in important international markets. CFT8919 is an orally bioavailable BiDAC degrader designed to exhibit potent and selective activity against EGFR L858R in patients with non-small cell lung cancer (NSCLC).
Pharmaceutical Technology
MAY 2, 2023
The orally bioavailable small molecule EGFR inhibitor ERAS-801 demonstrated significant central nervous system (CNS) penetration in animal trials. This newly granted status helps Erasca to facilitate the development and review of ERAS-801, thereby accelerating the therapy’s reach to patients.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Outsourcing Pharma
JANUARY 24, 2023
Evidence shows that animal models currently dominating bioavailability estimates are poor predictors and human, cell-based multi-organ microphysiological systems (MPS) should be investigated, CN Bio says.
XTalks
OCTOBER 2, 2024
With positive outcomes in preclinical models, EB-003 has confirmed oral bioavailability, adding to its therapeutic potential. Enveric is set to file an Investigational New Drug (IND) application by the third quarter of 2025, with plans to start clinical development by the end of the year.
Pharmaceutical Technology
FEBRUARY 13, 2023
However, there is a high level of attrition during the pharmaceutical research and development process, which is an indicator of the vast number of potential drug substances considered for progression. Therefore, it is vital to choose molecules for pharmaceutical development very carefully.
pharmaphorum
JANUARY 29, 2021
Lilly is paying $20 million upfront for exclusive rights to AK1780, a P2X7 receptor antagonist in early-stage clinical development for neuroinflammatory pain conditions, outside Japan and China. While tanezumab is an antibody and has to be delivered by subcutaneous injection, AK1780 is orally bioavailable.
pharmaphorum
NOVEMBER 9, 2022
This novel pathological mechanism is being targeted by NRG and was identified by the company’s collaborator, Professor Seth Masters of Melbourne, Australia’s Walter and Eliza Hall Institute of Medical Research (WEHI). Following the Series A financing, Professor Masters joins NRG’s management team as vice president of discovery biology.
Expert insights. Personalized for you.
130 
Let's personalize your content